Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Daiichi’s huge ADC deal with Merck; mixed data for Rybrevant at ESMO; Pfizer girds for cost cuts; myeloma helps J&J’s Q3; and five key points for cell and gene Meeting on the Mesa.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 20 October 2023, including: Daiichi Sankyo Co., Ltd.’s huge ADC deal with Merck & Co., Inc.; mixed data for Rybrevant at ESMO; Pfizer Inc. girds for cost cuts; myeloma helps Johnson & Johnson’s Q3; and five key points from the cell and gene Meeting on the Mesa.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Daiichi In Massive $22bn Global Deal With Merck & Co For Three ADCs" - Scrip, 20 Oct, 2023.)
(Also see "ESMO 23: MARIPOSA Data Blunt J&J’s Rybrevant Threat To Tagrisso" - Scrip, 18 Oct, 2023.)
(Also see "‘It’s A Very Different Story,’ Pfizer CEO Bourla Says Of Cuts To Match COVID Revenue" - Scrip, 16 Oct, 2023.)
(Also see "J&J’s Multiple Myeloma Launches Pick Up Momentum" - Scrip, 17 Oct, 2023.)
(Also see "Five Key Points From Cell & Gene Meeting On The Mesa" - Scrip, 13 Oct, 2023.)